{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:47:56Z","timestamp":1776926876840,"version":"3.51.2"},"reference-count":23,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2005,6,15]],"date-time":"2005-06-15T00:00:00Z","timestamp":1118793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p> <jats:italic>Background:<\/jats:italic> Data regarding costs of outpatient and office\u2010based care, as well as out\u2010of\u2010pocket expenses, for psoriasis patients in Germany are not available. Aim of this study was to assess average annual cost and cost per flare of outpatient and office\u2010based care for patients with moderate to severe chronic psoriasis vulgaris from several perspectives.<\/jats:p><jats:p> <jats:italic>Methods:<\/jats:italic> In this multi\u2010center, cross\u2010sectional, retrospective and prospective cost\u2010of\u2010illness study, direct (medical and non\u2010medical) and indirect costs were considered from patient, third\u2010party payer (TPP) and societal perspectives.<\/jats:p><jats:p> <jats:italic>Results:<\/jats:italic> Out of 227\u2005patients enrolled consecutively in 17\u2005centers, 192\u2005cases could be analyzed. On average, TPP reimbursed 864\u2005\u20ac per patient annually, 60\u2003% for prescribed medication and 22\u2003% for hospitalization. Patients spent 596\u2005\u20ac yearly mainly for alternative therapies and OTC\u2010medication\/skin care products as well as for additional expenses (e.\u2003g. ultraviolet lamp, clothes or cleaning agents). Indirect costs per patient amounted to 1,440\u2005\u20ac yearly. Total annual costs per patient were 2,866\u2005\u20ac and 4,985\u2005\u20ac if treated with systemic drugs additionally. 1,173\u2005\u20ac if treated topically and\/or with phototherapy.<\/jats:p><jats:p> <jats:italic>Conclusions:<\/jats:italic> The relatively high average annual costs per patient indicate need for efficient control of psoriasis. This cost\u2010of\u2010illness study provides basic data for further decision making, including economic assessment of innovative therapies for psoriasis.<\/jats:p>","DOI":"10.1111\/j.1610-0387.2005.05729.x","type":"journal-article","created":{"date-parts":[[2005,6,15]],"date-time":"2005-06-15T11:28:36Z","timestamp":1118834916000},"page":"511-518","source":"Crossref","is-referenced-by-count":62,"title":["Cost\u2010of\u2010illness in patients with moderate and severe chronic psoriasis vulgaris in Germany"],"prefix":"10.1111","volume":"3","author":[{"given":"Karin","family":"Berger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Ehlken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kugland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,6,15]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.2002.00611.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.119669"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0926-9959.2001.00257.x"},{"key":"e_1_2_6_5_2","unstructured":"TraupeH RobraB.Gesundheitsberichterstattung des Bundes. Heft 11: Psoriasis.Robert\u2010Koch\u2010Institut Berlin2002."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.03207.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03469.x"},{"key":"e_1_2_6_9_2","first-page":"280","article-title":"The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient\u2010membership survey","volume":"137","author":"Krueger G","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)70172-5"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630310019382"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.106374"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_2_6_14_2","unstructured":"Einheitlicher Bewertungsma\u00dfstab (EBM) Stand: 1. Oktober 2001 [German tariff list for medical services]; Deutscher \u00c4rzte\u2010Verlag K\u00f6ln."},{"key":"e_1_2_6_15_2","unstructured":"Rote Liste. Arzneimittelverzeichnis f\u00fcr Deutschland [Tariff list for drugs in Germany]. Editio Cantor Verlag Aulendorf 2002."},{"key":"e_1_2_6_16_2","unstructured":"Anonymus.Zahlenbericht 2001\/2002. Verband der Privaten Krankenversicherer [Report 2001\/2002. Association of private health insurances]. K\u00f6ln 2002."},{"key":"e_1_2_6_17_2","unstructured":"Statistisches Bundesamt: Fachserie 18 Reihe 1.3 2001."},{"key":"e_1_2_6_18_2","first-page":"320","article-title":"Italian Association for Studies on Psoriasis: The cost of hospital\u2010related care of patients with psoriasis in Italy based on the AISP study","volume":"15","author":"Finzi AF","year":"2001","journal-title":"JEAVD"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02076.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04920.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)62007-4"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.127247"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)80057-7"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70406-8"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1610-0387.2005.05729.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1610-0387.2005.05729.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T01:25:14Z","timestamp":1697073914000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1610-0387.2005.05729.x"}},"subtitle":["Krankheitskosten bei Patienten mit mittelschwerer und schwerer chronischer Psoriasis vulgaris in Deutschland"],"short-title":[],"issued":{"date-parts":[[2005,6,15]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1111\/j.1610-0387.2005.05729.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1610-0387.2005.05729.x","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,15]]}}}